drugset / Trial / NCT06617923
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2
Recruiting
18 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Impact Therapeutics, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Timeline
- Start
- 2025-02-06
- Primary completion
- 2027-10
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMP4297 | Unknown | 80 mg | Oral |
| Subject | Temozolomide | Small molecule | 20 mg | Oral |